We thank Eyüboglu for his letter. 1 The neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were investigated in an attempt to find inexpensive and readily available markers for inflammation and cardiovascular (CV) prognosis. 2 The NLR was shown to be a potential prognostic marker in patients undergoing primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI). 3 The PLR is also associated with adverse CV outcomes. 4 As we did not have enough data about medical treatment, we highlighted the lack of data on medication of patients as a limitation of our study. 2 As specified by Eyüboglu, 1 guidelines suggest to use dual antiplatelet therapy, statins, b-blockers and if necessary, reninangiotensin system inhibitors, for preventing worse outcomes in patients with STEMI. 5 In order to eliminate these limitations and to confirm the predictive values of NLR and PLR for prognosis in patients with STEMI undergoing pPCI, multicenter, large-scale, prospective and randomized studies are needed as mentioned before.
